Amplia CEO, Dr John Lambert spoke with Annette Beacher and David Scutt from Ausbiz this week about the Company's $12.4 million capital raising announcement, and plans to progress AMP945 to Phase 2 clinical trials in pancreatic cancer patients in 2022.
